Latest New Zealand News

Radiopharm Theranostics has completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan, both at $0.03 per share, to fund drug manufacturing and clinical trials through 2027.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Zip Co Limited has increased its on-market share buy-back limit from $50 million to $100 million, reflecting confidence in its financial strength and growth prospects. The move underscores the company’s commitment to capital management and shareholder returns.

Zip Co Limited has reported a near doubling in cash earnings for Q1 FY26, driven by robust transaction growth and improved operating leverage, particularly in the US market. The company also doubled its share buy-back program and raised its US transaction volume growth guidance.

Reece Limited has completed a $365 million off-market share buy-back, repurchasing 4.3% of its shares at $13 each with no scale-back applied. This move returns excess capital to shareholders while preserving financial flexibility for future growth.

Infratil Limited is expanding its footprint in New Zealand's energy sector by acquiring an additional 4.92% stake in Contact Energy for NZ$437.7 million, combining debt and equity financing.

Shriro Holdings announces a $5 million off-market share buy-back at a 14.1% premium, signaling a pivot from acquisitions to expanding its BBQ range globally. The move aims to return excess capital to shareholders while maintaining flexibility for further buy-backs.

WAM Income Maximiser Limited has launched a Share Purchase Plan offering eligible shareholders a discounted entry point to increase their holdings, aiming to raise up to $48.1 million to fuel portfolio growth and deliver steady dividends.

WAM Income Maximiser Limited is offering eligible shareholders the chance to buy up to $30,000 in shares at a discount, aiming to raise $48.1 million to fuel growth and support monthly dividends.

De.mem Limited has acquired Core Chemicals Pty Ltd for $2.68 million, nearly doubling its EBITDA and positioning itself to capitalise on a surging gold sector. The deal combines strong recurring revenues with significant synergy potential.

Coventry Group reports a 4.5% increase in Q1 FY26 sales alongside a notable EBITDA turnaround, underpinned by a $10 million cost-out program and fresh executive appointments.

INOVIQ Limited has completed a $9.5 million placement to institutional investors and launched a $2 million Share Purchase Plan for existing shareholders, aiming to bolster its cancer diagnostics and therapeutics pipeline.